<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Differentiation syndrome associated with treatment of acute leukemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Differentiation syndrome associated with treatment of acute leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Differentiation syndrome associated with treatment of acute leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Remzi Bag, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bob Lowenberg, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Differentiation syndrome (DS; originally called "retinoic acid syndrome") is a potentially fatal complication of treatment of acute promyelocytic leukemia (APL) with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a>, treatment of acute myeloid leukemia (AML) with inhibitors of isocitrate dehydrogenase (IDH; ie, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>), and treatment of AML with mutant FLT3 (Fms-related tyrosine kinase 3) with <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>. </p><p>The clinical presentation, diagnosis, and treatment of differentiation syndrome will be discussed here. </p><p>Clinical manifestations, diagnosis, and treatment of APL and an overview of AML are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/94786.html" rel="external">"Acute myeloid leukemia in adults: Overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>DS occurs in roughly one-quarter of patients with acute promyelocytic leukemia (APL) treated with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO), up to one-fifth of patients treated with IDH inhibitors (ie, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>) for acute myeloid leukemia (AML), and a small fraction of those treated with <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a> for AML. Factors that predict development of DS are not well defined.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute promyelocytic leukemia</strong> – DS is reported in approximately one-quarter of patients who are treated with ATRA for APL, but the incidence has ranged from 2 to 48 percent; the wide range in incidence reflects differences in induction regimens, preventive measures, and different diagnostic criteria [<a href="#rid1">1-10</a>]. For patients treated with ATO for APL, the incidence of DS ranged from 7 to 31 percent [<a href="#rid5">5,11-14</a>]. DS can also occur in patients with relapsed APL who were treated with ATRA and/or ATO [<a href="#rid15">15</a>]. The incidence of DS was similar in both arms of a trial in which patients were randomly assigned to ATRA plus ATO versus ATRA plus chemotherapy [<a href="#rid16">16</a>]. DS has not been reported with ATO treatment of non-APL malignancies or during consolidation or maintenance phase of APL, because the syndrome depends on the presence of leukemic blasts and/or promyelocytes [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myeloid leukemia</strong> – DS has been reported in 10 to 19 percent of adults with <em>IDH</em>-mutated relapsed or refractory AML treated with the IDH inhibitors, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, or <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a> [<a href="#rid18">18-23</a>], and in 17 percent of patients with newly diagnosed <em>IDH</em>-mutated AML treated with ivosidenib and <a class="drug drug_general" data-topicid="8797" href="/z/d/drug information/8797.html" rel="external">azacitidine</a> [<a href="#rid24">24</a>]. DS was reported in 3 percent of patients treated with <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>, an inhibitor of mutant FLT3 [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Elevated white blood cell (WBC) count is frequently present at the onset of DS, but DS can also occur without leukocytosis. In one study of APL, development of DS was associated with elevated levels of WBC, creatinine, lactate dehydrogenase, and peripheral blood blast count during treatment, according to multivariate analysis [<a href="#rid17">17</a>]. Other reported associations include elevated WBC count at presentation, rapidly rising WBC count, expression of CD13 or CD11b on APL blasts, and elevated body mass index (BMI) [<a href="#rid2">2,6,7,26-33</a>]. The incidence of DS does not appear to be related to the dose of ATRA or ATO, concurrent use of chemotherapy, or drugs that affect cytochrome P450 activity. In one study of APL, multivariate analysis indicated that fatal outcomes with DS were associated with poor performance status and low serum albumin [<a href="#rid34">34</a>]. No factors have been shown to predict development of DS in patients treated with IDH inhibitors.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The etiology of DS is incompletely understood, but DS has been linked to a large burden of maturing myeloid cells and their production of inflammatory cytokines.</p><p>In acute promyelocytic leukemia (APL), <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO) can induce maturation of promyelocytes and promote tissue infiltration [<a href="#rid35">35</a>]. Other factors that may contribute to DS include a systemic inflammatory response associated with increased cytokine expression, endothelial damage with capillary leak syndrome, and occlusion of the microcirculation. Inflammatory vasoactive cytokines that have been implicated in DS include interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor alpha, and CCL2 [<a href="#rid36">36,37</a>]. Release of cathepsin G, a serine protease that enhances capillary permeability, may contribute to capillary damage [<a href="#rid38">38</a>]. ATRA and ATO act through the aberrant retinoid receptor PML-RARA to induce differentiation of APL promyelocytes, increase chemokine production, and upregulate leukocyte integrins, which increase adherence to capillary endothelium and enhance organ infiltration [<a href="#rid39">39-44</a>]. The molecular pathology of APL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4523.html" rel="external">"Molecular biology of acute promyelocytic leukemia", section on 'Retinoic acid and the retinoic acid receptor'</a>.)</p><p>Less is understood about the cause of DS associated with inhibitors of mutant isocitrate dehydrogenase (IDH; ie, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>) and the FLT3 inhibitor, <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>. However, these agents can promote differentiation of myeloid blasts in patients with acute myeloid leukemia (AML) [<a href="#rid45">45-48</a>].</p><p class="headingAnchor" id="H950592094"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Lung histopathology in patients with DS reveals interstitial infiltration with maturing myeloid cells [<a href="#rid3">3,26</a>]. Patients with fatal DS may also have septal edema, diffuse alveolar damage, intra-alveolar hemorrhage, and capillaritis (small vessel inflammation) [<a href="#rid4">4,39</a>]. Post-mortem studies have also revealed extensive infiltrates of myeloid cells in other organ systems, including lymph nodes, spleen, liver, and pericardium [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1587882141"><span class="h2">Onset of DS</span><span class="headingEndMark"> — </span>The onset of clinical manifestations of DS can range from days to weeks after beginning treatment, but findings generally arise earlier in patients with severe disease. The type of leukemia and induction therapy influence the timing of DS onset.</p><p class="bulletIndent1"><span class="glyph">●</span>DS associated with acute promyelocytic leukemia (APL) generally occurs 7 to 12 days after starting induction therapy, but can appear as early as the first day of treatment [<a href="#rid8">8,10,49</a>]. In one study, DS occurred a median of 12 days after starting <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA; range 0 to 46 days) but followed a bimodal pattern; DS began in 46 percent of patients within the first week, while symptoms developed during the third week or beyond for 38 percent [<a href="#rid50">50</a>]. Severe DS typically begins earlier (median six days) than moderate DS (median 15 days). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reported median onsets of DS complicating treatment of acute myeloid leukemia (AML) with <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a> are 19 to 30 days from initiation (range 1 to 129 days) [<a href="#rid19">19,21</a>]. Median times of onset of DS reported with <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> treatment are 20 to 29 days (range 1 to 78 days) [<a href="#rid21">21,51,52</a>]. DS following treatment with <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a> for AML with mutant <em>FLT3</em> occurred 2 to 75 days after beginning treatment [<a href="#rid25">25</a>]. The following studies illustrate typical DS rates and onset patterns in AML:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 153 IDH1 inhibitor-naïve patients who received monotherapy with <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a> for relapsed or refractory <em>IDH1</em>-mutant AML, DS adverse events occurred in 22 (14 percent) patients, with 14 (9 percent) grade ≥3 (<a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">table 1</a>) and 1 fatal case reported [<a href="#rid22">22</a>]. For most affected patients, DS occurred within the first two cycles of treatment, with a median time to first event of 18 days (range, 1 to 561).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a separate trial, 146 newly diagnosed <em>IDH1</em>-mutant AML patients were randomized 1:1 to receive <a class="drug drug_general" data-topicid="8797" href="/z/d/drug information/8797.html" rel="external">azacitidine</a> and either <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> or placebo [<a href="#rid52">52</a>]. The percentage of patients with DS of any grade (<a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">table 1</a>) was 14 percent with ivosidenib and azacitidine (with no grade ≥4 events) and 8 percent with placebo and azacitidine (including one grade 4 event). The median time to onset of DS of any grade in the ivosidenib-and-azacitidine group was 20 days (range, 3.0 to 33).</p><p></p><p class="headingAnchor" id="H3829303931"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Typical clinical findings of DS include dyspnea, fever, peripheral edema, hypotension, weight gain, pleuro-pericardial effusion, acute renal failure, musculoskeletal pain, and hyperbilirubinemia [<a href="#rid3">3,5,26,50,53,54</a>]. Less commonly, DS may be associated with pulmonary hemorrhage or Sweet syndrome (acute febrile neutrophilic dermatosis) [<a href="#rid4">4,39,55-57</a>]. No symptoms or signs distinguish DS caused by treatment of APL from that caused by treatment of AML. (See  <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>The frequency of clinical findings varies with the severity of the syndrome. Among 739 patients with APL, the following findings were noted in moderate and severe DS: dyspnea (59 and 95 percent, respectively), edema (53, 81 percent), unexplained fever (53, 74 percent), weight gain &gt;5 kg (38, 68 percent), and hypotension (12, 39 percent) [<a href="#rid50">50,58</a>]. An erythematous rash may be present [<a href="#rid18">18,41</a>].</p><p>Headache can be a manifestation of pseudotumor cerebri, which is a potential complication of treatment with ATRA and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO). Patients with headache and/or visual disturbance should have a funduscopic examination promptly to identify papilledema or other manifestations of pseudotumor cerebri, which is a medical emergency. (See  <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults", section on 'High intracranial pressure'</a>.)</p><p class="headingAnchor" id="H244006523"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Abnormal hematologic parameters and chemistries are common in DS but differ slightly between APL and AML. </p><p>Elevated white blood cell (WBC) count, anemia, thrombocytopenia, and coagulopathy are common in DS associated with APL, but some of these abnormalities may be due to the underlying leukemia and/or concomitant chemotherapy [<a href="#rid5">5,6,26,50</a>]. In one series of DS in APL, the median WBC count was 31,000/microL (range 6800 to 72,000/microL) at the onset of the syndrome [<a href="#rid26">26</a>]. </p><p>Among patients with AML treated with <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, approximately 40 percent had concomitant leukocytosis [<a href="#rid19">19</a>], while only 10 percent of those treated with <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> developed leukocytosis [<a href="#rid18">18</a>].</p><p>Renal failure was reported in 9 and 46 percent of patients with moderate and severe DS, respectively, in a large series of patients with APL [<a href="#rid50">50,58</a>].</p><p class="headingAnchor" id="H1026597842"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Chest radiograph abnormalities are common in DS, but findings may differ based on the severity of the syndrome. Pleural effusions appear to be more common in association with ATRA/ATO than with isocitrate dehydrogenase (IDH) inhibitors. </p><p>Chest radiograph findings attributable to DS include increased cardiothoracic ratio (87 percent), increased vascular pedicle width (87 percent), septal lines and peribronchial cuffing (60 percent), diffuse ground glass opacity (60 percent), parenchymal consolidation (47 percent), nodular opacities (47 percent), air bronchogram (33 percent), and pleural effusion (73 percent) [<a href="#rid4">4,50</a>]. Approximately 40 percent of patients with DS have a clear chest radiograph at presentation, although only 11 percent of patients with severe disease have a clear chest radiograph [<a href="#rid50">50</a>]. In a large series of patients with APL, patients with moderate and severe DS had pulmonary opacities on chest radiograph in 38 and 81 percent, respectively, pleural effusion in 27 and 58 percent, and pericardial effusion in 11 and 23 percent [<a href="#rid50">50,58</a>].</p><p>Pleural effusions were reported in 12 percent of patients treated with <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> and in 42 percent treated with <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a> [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H630682160"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>DS should be suspected in patients with any of the characteristic features (eg, unexplained fever, hypotension, weight gain, dyspnea, radiographic pulmonary opacities, pleural/pericardial effusion, and/or renal insufficiency) in the setting of acute promyelocytic leukemia (APL) or acute myeloid leukemia (AML) treated with differentiation agents. (See <a class="local">'Prompt initiation of glucocorticoids'</a> below and <a class="local">'Additional testing for more severe or progressive disease'</a> below.)</p><p class="headingAnchor" id="H2694556358"><span class="h2">Initial steps in all patients</span><span class="headingEndMark"> — </span>Importantly, treatment of DS should begin at the time that DS is first suspected, even as diagnostic testing is being performed. (See <a class="local">'Prompt initiation of glucocorticoids'</a> below.)</p><p>Daily weights and fluid balance should be monitored. In addition, the following studies should be obtained in all patients suspected of DS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong> – Complete blood count (CBC) with differential count, prothrombin time (PT), partial thromboplastin time (PTT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemistry</strong> – Serum electrolytes, blood urea nitrogen, creatinine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxygenation</strong> – Pulse oximetry or arterial blood gas </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Blood cultures </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Chest radiograph </p><p></p><p class="headingAnchor" id="H2711828672"><span class="h2">Additional testing for more severe or progressive disease</span><span class="headingEndMark"> — </span>Additional testing is appropriate for patients who present with more severe respiratory insufficiency, fever, or hypotension, and those who do not respond to initial glucocorticoid treatment within 24 hours. (See <a class="local">'Prompt initiation of glucocorticoids'</a> below.)</p><p>As the diagnosis of DS is based on a constellation of nonspecific clinical features, the main goals of additional testing are to identify processes in the differential diagnosis of DS, such as infection, heart failure, pulmonary hemorrhage, or thromboembolism, realizing that patients may have more than one process contributing to symptoms. (See <a class="local">'Differential diagnosis'</a> below.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic testing</strong> – Specific laboratory studies to evaluate infection in leukemic patients with fever are informed by the clinical findings and are described separately. (See  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever", section on 'Patient evaluation'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography</strong> (CT) can clarify the pattern, extent, and location of radiographic abnormalities, if needed to guide bronchoscopic evaluation and can help identify pleural and pericardial effusions. The use of CT to evaluate respiratory insufficiency is described separately. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea", section on 'Chest computed tomography'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoscopy/bronchoalveolar lavage (BAL)</strong> can be helpful for evaluation of pulmonary infection or pulmonary hemorrhage but is generally reserved for patients who require intubation and mechanical ventilation. BAL can usually be performed safely, even with thrombocytopenia and/or coagulopathy [<a href="#rid50">50</a>]. When possible, the area of lung with the greatest degree of radiographic abnormality should be lavaged. The specimens should be processed for special stains and culture for bacterial and fungal infection, and also PCR and culture for viral infections (<a class="graphic graphic_table graphicRef70685" href="/z/d/graphic/70685.html" rel="external">table 2</a>). BAL may also detect alveolar hemorrhage as a complication of severe differentiation syndrome (<a class="graphic graphic_picture graphicRef61103" href="/z/d/graphic/61103.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates", section on 'Lung sampling'</a>.)</p><p></p><p class="bulletIndent1">Endobronchial or transbronchial biopsy should be avoided because of the increased risk of hemorrhage in the setting of thrombocytopenia and/or coagulopathy. (See  <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">"Flexible bronchoscopy in adults: Indications and contraindications", section on 'Contraindications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac evaluation</strong> – Patients with dyspnea, edema, and/or hypotension that may be caused by reduced cardiac output or excess fluid accumulation should be evaluated with brain natriuretic peptide (BNP), electrocardiogram (EKG), and/or echocardiogram to detect heart failure, pericardial effusion, or dysrhythmias, as described separately. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p>Patients with DS are at risk for acute kidney injury due to capillary leakage and hypotension from intravascular depletion. Close monitoring of renal function and intravascular volume is prudent. (See  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H566845706"><span class="h2">Avoidance of invasive procedures</span><span class="headingEndMark"> — </span>It is important to avoid nonessential invasive procedures (eg, thoracentesis, lung biopsy, kidney biopsy) because patients with APL or AML have a high risk of bleeding due to associated coagulation defects and bleeding disorders. (See  <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults", section on 'Coagulopathy and APL'</a> and  <a class="medical medical_review" href="/z/d/html/4510.html" rel="external">"Acute myeloid leukemia: Overview of complications", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H1507014665"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A prompt clinical response to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is strong evidence for uncomplicated DS and may obviate the need for more invasive or expensive investigations. The diagnosis of DS is based on the clinical presentation and setting (differentiation therapy for leukemia) and is supported by a response to treatment and exclusion of alternate diagnoses. </p><p>In the setting of treatment of acute promyelocytic leukemia (APL) with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO) or treatment of acute myeloid leukemia (AML) with <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a> or <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, a presumptive diagnosis (based on ≥1 clinical features) enables initiation of glucocorticoid treatment while pursuing evaluation of other potential causes. The presence of three or more features is sufficient for a confident clinical diagnosis of DS in the absence of another cause [<a href="#rid1">1,3,18,19,59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever ≥38° C</p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain &gt;5 kg</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea </p><p class="bulletIndent1"><span class="glyph">●</span>Radiographic opacities</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural or pericardial effusion</p><p class="bulletIndent1"><span class="glyph">●</span>Acute renal failure</p><p></p><p>The exact criteria for the diagnosis of DS have not been formally established. Other sets of diagnostic criteria include combinations of these features, but vary in the number required to establish the diagnosis [<a href="#rid26">26,50,60</a>]. </p><p>Of note, features of DS overlap with other processes that are common in this setting, and more than one disease process (eg, DS and infection) can contribute to symptoms and signs. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In general, disease severity correlates with the number of clinical features that are present [<a href="#rid50">50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong>: ≥4 clinical features </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate</strong>: 3 clinical features</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indeterminate</strong>: 1 to 2 clinical features</p><p></p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Clinical features of DS overlap substantially with other processes, such as infection/sepsis, heart failure, and pulmonary thromboembolism that occur in this setting. Treatment of DS should begin at the time that DS is first suspected, even as other causes are being evaluated. (See <a class="local">'Prompt initiation of glucocorticoids'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection/sepsis</strong> − Both infection/sepsis and DS can present with fever, hypotension, respiratory distress, and/or radiographic pulmonary opacities. Neither condition can be conclusively distinguished on the basis of routine initial laboratory testing and chest radiograph. The evaluation for infection should include peripheral blood cultures, sputum stains and cultures, nasal swab for viral PCR, and serum and urine tests for specific bacterial, fungal, and viral infections. Empiric antibiotic therapy is often initiated pending study results.</p><p></p><p class="bulletIndent1">If the patient has respiratory failure or does not respond to empiric antibiotics, flexible bronchoscopy with bronchoalveolar lavage may help to identify an organism. Evaluation of fever and empiric antibiotic therapy are described separately. (See  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a> and  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Empiric therapy'</a> and <a class="local">'Treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboembolism</strong> − Clinical features of pulmonary embolism (PE)/deep vein thrombosis (DVT; eg, dyspnea/hypoxia, hypotension, peripheral edema, leg swelling, hemoptysis) may be indistinguishable from those of DS. Furthermore, there is an increased risk of thrombosis in DS [<a href="#rid17">17</a>]. Pulmonary embolism should be suspected in patients with evidence of deep vein thrombosis (lower extremity or related to central venous catheter) and in those with hypoxemia that is out of proportion to the extent of the radiographic opacities. Evaluation of DVT/PE is described separately. (See  <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> − Heart failure can be associated with dyspnea, hypotension, edema, and abnormalities on chest radiograph that may be indistinguishable from findings of DS. Furthermore, patients with acute leukemia may have ventricular dysfunction from prior chemotherapy. Clinical evaluation, measurement of brain natriuretic peptide (BNP), echocardiography, and/or computed tomography (CT) should distinguish heart failure due to left ventricular function, pericardial effusion, or dysrhythmia from DS. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alveolar hemorrhage</strong> − Alveolar hemorrhage is a well-described complication of acute leukemia in patients with diffuse intravascular coagulation, although the frequency has markedly decreased since introduction of differentiation therapy [<a href="#rid55">55</a>]. Alveolar hemorrhage is also described in patients with DS and normal clotting studies and those with lung infection [<a href="#rid61">61</a>]. In a patient with DS who develops diffuse pulmonary opacities, it can be difficult to determine whether the findings are caused by DS, alveolar hemorrhage, pneumonia, or a combination. However, a specific diagnosis of alveolar hemorrhage (eg, by bronchoalveolar lavage [BAL]) is generally not needed. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug allergy</strong> − Allergy to antibiotics or other medications given prior to the onset of DS can cause fever, rash, capillary leak, and dyspnea. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury</strong> − Acute kidney injury is one of the criteria of DS, but can also be a consequence of hypotension, decreased cardiac output, infection, or drug toxicity. It is important to avoid nonessential kidney biopsy to reduce the risk of hemorrhage in this setting. The evaluation of acute kidney injury is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients", section on 'Evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>DS is a potentially fatal complication of acute promyelocytic leukemia (APL) treated with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO), and acute myeloid leukemia (AML) treated with inhibitors of mutant isocitrate dehydrogenase (IDH; ie, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>) or mutant FLT3 (<a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>). It is important to have a high degree of suspicion for the diagnosis, and to initiate treatment of DS concurrently with the diagnostic evaluation (<a class="graphic graphic_algorithm graphicRef120780" href="/z/d/graphic/120780.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H1491367901"><span class="h2">Prompt initiation of glucocorticoids</span><span class="headingEndMark"> — </span>For all patients suspected of having DS (one or more clinical features), we recommend prompt treatment with systemic glucocorticoids concurrently with the diagnostic evaluation, rather than waiting to treat until completion of the diagnostic evaluation [<a href="#rid59">59,62</a>]. This recommendation is based on the favorable balance of modest toxicity of therapy weighed against a generally prompt and robust response; in contrast, DS can progress rapidly if treatment is delayed. (See <a class="local">'Diagnosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing</strong> – We typically initiate treatment with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 10 mg, orally or intravenously, every 12 hours [<a href="#rid59">59</a>]. Most patients improve substantially within 12 to 24 hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate response to initial treatment</strong> – If the patient has not improved substantially within 24 hours, the dosing frequency can be increased to every six hours, while reassessing the possibility of an alternate diagnosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration and tapering</strong> – <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> (or the equivalent) is continued at full dose for at least three days or until fever, dyspnea, and hypoxemia have resolved, followed by a tapering course (eg, reducing by 50 percent every two to three days). Occasionally, DS may recur as the glucocorticoids are tapered or discontinued. (See <a class="local">'Recurrent DS'</a> below.)</p><p></p><p class="bulletIndent1">Potential toxicities of glucocorticoid treatment include hyperglycemia, insomnia, depression, emotional instability, and immunosuppression, but severe toxicity is rare. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – There are no randomized trials of early treatment with systemic glucocorticoids versus delayed therapy for DS in APL. However, retrospective and prospective studies of ATRA and/or ATO report that prompt treatment with steroids has reduced DS-associated mortality to approximately 1 percent [<a href="#rid1">1,9,26,50,59,60,63,64</a>]. As an example, one study reported 0.2 percent DS-associated mortality among 240 patients with APL who received ATRA plus <a class="drug drug_general" data-topicid="8549" href="/z/d/drug information/8549.html" rel="external">idarubicin</a> induction therapy; DS was diagnosed in 15 percent of patients in this study based on the presence of five clinical criteria [<a href="#rid9">9</a>]. In contrast, two studies of APL that were performed prior to the routine early administration of steroids were each associated with 9 percent DS-associated mortality [<a href="#rid3">3,6</a>]. </p><p></p><p class="bulletIndent1">In a series of 281 patients treated with <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a> for relapsed or refractory AML, there were no DS-associated deaths among the 12 percent of patients who developed DS and were promptly treated with steroids [<a href="#rid19">19</a>]. There were no DS-associated deaths among the 4 percent of 179 patients who developed DS during treatment with <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> for relapsed or refractory AML; all patients received prompt initiation of glucocorticoids [<a href="#rid51">51</a>]. </p><p></p><p>Our approach is consistent with that proposed for DS by the National Comprehensive Cancer Network (NCCN) and the European Leukemia Network [<a href="#rid62">62,65,66</a>]. </p><p class="headingAnchor" id="H1791005700"><span class="h2">Management of differentiation agents</span><span class="headingEndMark"> — </span>We suggest continuing differentiation agents in the majority of patients who develop DS. As an exception, differentiation agents may need to be held temporarily in patients with severe manifestations of DS, such as life-threatening organ dysfunction (eg, hypoxemia requiring ventilatory support, hypotension requiring vasopressor therapy, acute renal failure). The suggestion to continue differentiation therapy in most patients is based on favorable outcomes with prompt initiation of glucocorticoids and the desire to achieve optimal outcomes for the leukemia by continuing therapy. </p><p>The decision to interrupt the differentiation therapy is also informed by the specific agent(s) used: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATRA and/or ATO</strong> – For patients with severe DS receiving ATRA and/or ATO, we suggest withholding these agents while continuing glucocorticoid therapy. ATRA/ATO are withheld until findings of severe DS have resolved (ie, ≤3 diagnostic criteria or resolution of organ failure), at which point they can be resumed and then continued until achievement of complete remission (CR) or completion of the minimum duration of remission induction therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ivosidenib</strong><strong>, </strong><strong>olutasidenib</strong><strong>, </strong><strong>enasidenib</strong><strong>, and </strong><strong>gilteritinib</strong><strong> </strong>– For patients receiving <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, or <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a> for AML, withdrawal of these agents is unlikely to be effective in the immediate term because of the prolonged half-lives of ivosidenib (estimated 97 hours), <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a> (estimated 67 hours), enasidenib (estimated 137 hours), and gilteritinib (113 hours) [<a href="#rid67">67,68</a>]. If needed, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> can be added to control leukocytosis, as discussed separately.</p><p></p><p class="headingAnchor" id="H3271948061"><span class="h2">Empiric antibiotics</span><span class="headingEndMark"> — </span>Prompt administration of broad-spectrum, empiric antibiotics is prudent in many patients with DS, especially those with neutropenia, fever, or progressive radiographic opacities. Empiric antibiotics are accompanied by rigorous evaluation for superimposed infection. Antibiotic therapy can be adjusted or discontinued, depending on microbiologic test results and response to therapy. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Empiric therapy'</a>.)</p><p class="headingAnchor" id="H3532281250"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Other supportive measures are important in optimal management of DS, including treatment for fluid overload, hypotension, respiratory or renal insufficiency, heart failure, bleeding, and other complications. Because the clinical findings of DS may be indistinguishable from those of other disorders that can complicate treatment of acute leukemia, patients should receive treatment for other conditions in the differential diagnosis, as described above. (See <a class="local">'Differential diagnosis'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid management</strong> <strong>and renal replacement therapy</strong> – For patients with weight gain or dyspnea due to DS, cautious diuresis is given as tolerated by the patient’s hemodynamic and renal status. Approximately 87 percent of patients with differentiation syndrome require diuretic therapy; in some cases this has led to rapid improvement [<a href="#rid50">50,69</a>]. For patients with kidney dysfunction related to hypotension, renal perfusion should be supported with intravenous fluids and/or vasopressors. Approximately 12 percent of patients need at least short-term renal replacement therapy [<a href="#rid50">50</a>]. Patients with hypotension that is not immediately responsive to fluid resuscitation should be evaluated for other causes of hypotension, as described separately. (See  <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Initial diagnostic evaluation'</a>.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of coagulopathy</strong> – For patients with fluid overload and high requirements for blood products to control coagulopathy, cryoprecipitate, fibrinogen, and other coagulation factor concentrates are preferred over fresh-frozen plasma, to limit the fluid burden [<a href="#rid59">59</a>]. The management of coagulopathy in APL is described separately. (See  <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults", section on 'Control of coagulopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxygenation and mechanical ventilation</strong> – Many patients will require supplemental oxygen, and some will require noninvasive or invasive mechanical ventilation to achieve adequate oxygenation [<a href="#rid17">17,26</a>].<strong> </strong>In the PETHEMA (Programa Español de Tratamientos en Hematología) studies, mechanical ventilation was needed in 26 percent of patients [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p></p><p class="headingAnchor" id="H1491369842"><span class="h2">Recurrent DS</span><span class="headingEndMark"> — </span>A small percentage of patients who respond to the initial course of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> will develop recurrent manifestations of DS upon tapering or discontinuation of dexamethasone [<a href="#rid10">10,26</a>]. For these patients, dexamethasone (10 mg intravenously, every 6 to 12 hours) is resumed until complete resolution of these manifestations [<a href="#rid59">59</a>]. As with initial therapy, other possible explanations, such as infection, heart failure, renal insufficiency, must be considered and/or treated. (See <a class="local">'Treatment'</a> above.)</p><p class="headingAnchor" id="H23"><span class="h1">PREVENTION OF DS</span><span class="headingEndMark"> — </span>We suggest <strong>not</strong> routinely treating with preventive steroids or other prophylactic therapy during induction therapy with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA), <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO), <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, or <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>. The suggestion against routine DS prophylaxis reflects our preference to avoid unnecessary toxicity and the lack of evidence that prophylaxis can improve outcomes. Rather, we suggest prompt administration of steroid therapy upon development of clinical findings consistent with DS, as described above. (See <a class="local">'Prompt initiation of glucocorticoids'</a> above.)</p><p>A potential role for prophylactic therapy for some or all of the duration of induction therapy, or for particular subsets of patients (eg, based on white blood cell [WBC] count, serum creatinine) has been examined in case series, but no randomized trials have been performed [<a href="#rid59">59</a>]. It remains unclear whether DS-preventive approaches result in meaningfully improved outcomes [<a href="#rid59">59</a>]. As an example, a review of three studies from Programa Español de Tratamientos en Hematología (PETHEMA) reported that steroid treatment was associated with a modest reduction of DS incidence, but no differences in DS-related mortality for acute promyelocytic leukemia (APL) treated with ATRA [<a href="#rid34">34</a>]. However, it is difficult to draw conclusions from this retrospective review that compared three different nonrandomized studies that administered steroids by various doses, routes, and schedules only for patients with WBC ≥5,000/microL.</p><p>The role of DS prophylaxis during treatment with isocitrate dehydrogenase (IDH) inhibitors has not been specifically examined and preventive therapy for DS was not included in studies of <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a> or <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> for acute myeloid leukemia (AML) [<a href="#rid19">19,51</a>]. Given the lower frequency of DS and relatively late onset, we do not prescribe preventive therapy in these patients.</p><p class="headingAnchor" id="H292566843"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117352.html" rel="external">"Society guideline links: Acute promyelocytic leukemia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116628.html" rel="external">"Society guideline links: Acute myeloid leukemia"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – Differentiation syndrome (DS) is a potentially fatal complication of treatment with differentiation agents in patients with acute promyelocytic leukemia (APL) or acute myeloid leukemia (AML). DS occurs in approximately one-quarter of patients with APL during induction therapy with <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and/or <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO), up to one-fifth of patients with AML treated with isocitrate dehydrogenase (IDH) inhibitors (eg, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="140314" href="/z/d/drug information/140314.html" rel="external">olutasidenib</a>), and in smaller numbers (estimated 3 percent) of patients with AML treated with <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a>. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The cause of DS is incompletely understood, but contributing factors include a systemic inflammatory response associated with increased cytokine expression, endothelial damage with capillary leak syndrome, occlusion of microcirculation, tissue infiltration, and other effects of maturation of large numbers of myeloblasts/promyelocytes. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Routine initial studies include a complete blood count with differential count, prothrombin time, partial thromboplastin time, serum electrolytes, blood urea nitrogen, creatinine, pulse oximetry and/or arterial blood gas, blood culture, and a chest radiograph. Further evaluation depends on the response to initial glucocorticoid therapy. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In the setting of treatment of APL or AML with a differentiation agent, a clinical diagnosis of DS can be made based on ≥3 of the following features, although one or more features not attributable to another cause is sufficient for a presumptive diagnosis (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever ≥38° C</p><p class="bulletIndent2"><span class="glyph">•</span>Weight gain &gt;5 kg</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension</p><p class="bulletIndent2"><span class="glyph">•</span>Dyspnea</p><p class="bulletIndent2"><span class="glyph">•</span>Radiographic opacities</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural or pericardial effusion</p><p class="bulletIndent2"><span class="glyph">•</span>Renal failure </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Clinical features of DS overlap substantially with other processes (eg, infection/sepsis, heart failure, pulmonary thromboembolism) that occur in this setting. Evaluation for other causes should proceed during initial treatment for presumptive DS. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prompt initiation of glucocorticoids</strong> – For patients clinically suspected of having DS, we recommend prompt treatment with systemic glucocorticoids rather than delaying treatment until completion of the diagnostic evaluation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The typical initial dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is 10 mg every 12 hours. (See <a class="local">'Prompt initiation of glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ongoing management of differentiation therapy</strong> – For most patients with DS, we suggest continuing differentiation agents while monitoring the response to glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Most patients will recover with prompt initiation of glucocorticoids, and continuation of differentiation agents enables optimal treatment of the leukemia. (See <a class="local">'Management of differentiation agents'</a> above.)</p><p></p><p class="bulletIndent2">For patients with severe DS (eg, respiratory or renal insufficiency requiring intensive care) or an inadequate response after 24 to 48 hours of glucocorticoid therapy, temporary interruption of ATRA and/or ATO is appropriate. Interruption of IDH or FLT3 inhibitors is less likely to be of benefit given their long half-life. (See <a class="local">'Management of differentiation agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive measures, including empiric antibiotics</strong> – Patients with fever in the setting of immunosuppression require prompt administration of broad-spectrum antibiotics and rigorous evaluation for superimposed infection. Supportive care for fluid overload, coagulopathy, bleeding, and organ failure is appropriate. (See <a class="local">'Empiric antibiotics'</a> above and <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – We suggest <strong>not</strong> routinely administering systemic glucocorticoids as attempted preventive or prophylactic treatment of DS during induction therapy with ATRA, ATO, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>, or <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">gilteritinib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).(See <a class="local">'Prevention of DS'</a> above.)</p><p></p><p class="headingAnchor" id="H4246270981"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steven Weinberger, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92:2712.</a></li><li><a class="nounderline abstract_t">Leblebjian H, DeAngelo DJ, Skirvin JA, et al. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2013; 37:747.</a></li><li><a class="nounderline abstract_t">Frankel SR, Eardley A, Lauwers G, et al. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292.</a></li><li><a class="nounderline abstract_t">Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol 2002; 178:475.</a></li><li><a class="nounderline abstract_t">Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18:2620.</a></li><li><a class="nounderline abstract_t">Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84:3843.</a></li><li><a class="nounderline abstract_t">Jeddi R, Ghédira H, Mnif S, et al. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010; 34:545.</a></li><li><a class="nounderline abstract_t">Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73:2946.</a></li><li><a class="nounderline abstract_t">Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014.</a></li><li><a class="nounderline abstract_t">Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88:1390.</a></li><li><a class="nounderline abstract_t">Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504.</a></li><li><a class="nounderline abstract_t">Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28:3866.</a></li><li><a class="nounderline abstract_t">Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011; 29:2753.</a></li><li><a class="nounderline abstract_t">Liu YF, Shen ZX, Chen X, et al. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)]. Zhonghua Xue Ye Xue Za Zhi 2003; 24:25.</a></li><li><a class="nounderline abstract_t">Lengfelder E, Lo-Coco F, Ades L, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia 2015; 29:1084.</a></li><li><a class="nounderline abstract_t">Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94:3015.</a></li><li><a class="nounderline abstract_t">Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis 2011; 3:e2011059.</a></li><li><a class="nounderline abstract_t">Norsworthy KJ, Luo L, Hsu V, et al. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clin Cancer Res 2019; 25:3205.</a></li><li><a class="nounderline abstract_t">Fathi AT, DiNardo CD, Kline I, et al. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol 2018; 4:1106.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf (Accessed on February 01, 2019).</li><li><a class="nounderline abstract_t">Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. Clin Cancer Res 2020; 26:4280.</a></li><li><a class="nounderline abstract_t">de Botton S, Fenaux P, Yee K, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv 2023; 7:3117.</a></li><li><a class="nounderline abstract_t">Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol 2023; 10:e46.</a></li><li><a class="nounderline abstract_t">DiNardo CD, Stein AS, Stein EM, et al. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 2021; 39:57.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf (Accessed on May 30, 2019).</li><li><a class="nounderline abstract_t">Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95:90.</a></li><li><a class="nounderline abstract_t">Jeddi R, Kacem K, Ben Neji H, et al. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology 2008; 13:142.</a></li><li><a class="nounderline abstract_t">Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90:1656.</a></li><li><a class="nounderline abstract_t">Santos FL, Dore AI, Lima AS, et al. [Hematological features and expression profile of myeloid antigens of acute promyelocytic leukemia patients: analysis of prognostic factors for development of the retinoic acid syndrome]. Rev Assoc Med Bras (1992) 2004; 50:286.</a></li><li><a class="nounderline abstract_t">Fenaux P, Castaigne S, Chomienne C, et al. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6 Suppl 1:64.</a></li><li><a class="nounderline abstract_t">Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012; 119:49.</a></li><li><a class="nounderline abstract_t">Wu JJ, Cantor A, Moscinski LC. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res 2007; 31:49.</a></li><li><a class="nounderline abstract_t">Cunha De Santis G, Tamarozzi MB, Sousa RB, et al. Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica 2007; 92:1615.</a></li><li><a class="nounderline abstract_t">de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395.</a></li><li><a class="nounderline abstract_t">Che-Pin Lin, Huang MJ, Chang IY, et al. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma 2000; 38:195.</a></li><li><a class="nounderline abstract_t">Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol 2010; 151:209.</a></li><li><a class="nounderline abstract_t">Dubois C, Schlageter MH, de Gentile A, et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 1994; 83:3264.</a></li><li><a class="nounderline abstract_t">Seale J, Delva L, Renesto P, et al. All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia 1996; 10:95.</a></li><li><a class="nounderline abstract_t">Nicolls MR, Terada LS, Tuder RM, et al. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158:1302.</a></li><li><a class="nounderline abstract_t">Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood 2009; 114:5512.</a></li><li><a class="nounderline abstract_t">Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994; 120:278.</a></li><li><a class="nounderline abstract_t">Hickstein DD, Hickey MJ, Collins SJ. Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation. J Biol Chem 1988; 263:13863.</a></li><li><a class="nounderline abstract_t">Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997; 90:2747.</a></li><li><a class="nounderline abstract_t">Marchetti M, Falanga A, Giovanelli S, et al. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol 1996; 93:360.</a></li><li><a class="nounderline abstract_t">Nassereddine S, Lap CJ, Tabbara IA. Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy. Onco Targets Ther 2019; 12:303.</a></li><li><a class="nounderline abstract_t">Yen K, Travins J, Wang F, et al. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discov 2017; 7:478.</a></li><li><a class="nounderline abstract_t">McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv 2019; 3:1581.</a></li><li><a class="nounderline abstract_t">Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 2012; 120:4205.</a></li><li><a class="nounderline abstract_t">Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85:1202.</a></li><li><a class="nounderline abstract_t">Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775.</a></li><li><a class="nounderline abstract_t">DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018; 378:2386.</a></li><li><a class="nounderline abstract_t">Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med 2022; 386:1519.</a></li><li><a class="nounderline abstract_t">Flombaum CD, Isaacs M, Reich L, et al. Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia. Am J Kidney Dis 1996; 27:134.</a></li><li><a class="nounderline abstract_t">Breccia M, Latagliata R, Carmosino I, et al. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica 2008; 93:1918.</a></li><li><a class="nounderline abstract_t">Raanani P, Segal E, Levi I, et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment. Leuk Lymphoma 2000; 37:605.</a></li><li><a class="nounderline abstract_t">Cox NH, O'Brien HA. Sweet's syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukaemia. Clin Exp Dermatol 1994; 19:51.</a></li><li><a class="nounderline abstract_t">Park CJ, Bae YD, Choi JY, et al. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med 2001; 16:218.</a></li><li><a class="nounderline abstract_t">de Botton S, Chevret S, Coiteux V, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003; 17:339.</a></li><li><a class="nounderline abstract_t">Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 2014; 123:2777.</a></li><li><a class="nounderline abstract_t">Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137.</a></li><li><a class="nounderline abstract_t">Yang CL, Shen K, Huang J. Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia. Chin Med J (Engl) 2018; 131:2386.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (Accessed on May 01, 2020).</li><li><a class="nounderline abstract_t">Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008; 33:331.</a></li><li><a class="nounderline abstract_t">Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24:5703.</a></li><li><a class="nounderline abstract_t">Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.</a></li><li><a class="nounderline abstract_t">Frankfurt O, Tallman MS. Strategies for the treatment of acute promyelocytic leukemia. J Natl Compr Canc Netw 2006; 4:37.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf.</li><li><a class="nounderline abstract_t">Yokokura M, Hatake K, Komatsu N, et al. Toxicity of tretinoin in acute promyelocytic leukaemia. Lancet 1994; 343:361.</a></li></ol></div><div id="topicVersionRevision">Topic 4351 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9763554" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23643326" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637024" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The "retinoic acid syndrome" in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804921" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radiologic features of all-trans-retinoic acid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893295" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949141" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19800119" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8199992" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242531" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695858" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075265" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644086" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646615" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679006" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627637" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220256" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692099" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346478" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32393603" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36724515" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36370742" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33119479" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33119479" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607690" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702871" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269786" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15499481" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : [Hematological features and expression profile of myeloid antigens of acute promyelocytic leukemia patients: analysis of prognostic factors for development of the retinoic acid syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : All trans retinoic acid treatment for patients with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049518" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16764927" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055984" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195095" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811463" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735400" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193361" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558945" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9769296" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828696" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8291820" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2901419" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326242" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639429" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30643428" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193778" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122910" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23012328" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7858250" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945964" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860938" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35443108" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546128" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945746" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042521" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8313637" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sweet's syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11769583" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592333" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24627526" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393132" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246736" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246736" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18613850" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Retinoic acid syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116939" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812465" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403403" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Strategies for the treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403403" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Strategies for the treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403403" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Strategies for the treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7905175" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Toxicity of tretinoin in acute promyelocytic leukaemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
